EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HSP90 Inhibitor, AT13387 Mitigates Chronic Lung Injury in Pre-Pubertal Mice: A Therapeutic Axis in Bronchopulmonary Dysplasia

Pavel A Solopov iD, Christiana Dimitropoulou, John D Catravas iD, Ruben M L Colunga Biancatelli iD

Biomolecules · 2026

DOI: 10.3390/biom16091320 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2026. Verfasst von Pavel A Solopov und 3 weiteren Autor:innen. Beteiligte Einrichtung: Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk, VA 23509, USA. Hauptthemen laut MEDLINE: HSP90 Heat-Shock Proteins, Lung Injury, Bronchopulmonary Dysplasia. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, Old Dominion Research Foundation, Pam and Rich Nuccitelli Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Exposure to hydrochloric acid (HCl) can provoke severe chronic pulmonary injury. Children are particularly vulnerable due to their smaller airways, higher respiratory rate, and stronger inflammatory response; yet no countermeasures exist for HCl-induced chronic lung injury in the pediatric population. We have previously demonstrated the involvement of HSP90 during HCl-induced lung injury in pre-pubertal (p24) mice, who develop stronger persistent inflammation with higher NLRP3 inflammasome activation, but less pulmonary fibrosis compared to adults. Here, we tested the hypothesis that post-treatment with the second-generation HSP90 inhibitor AT13387 (Onalespib), administered subcutaneously beginning 24 h after HCl instillation, would prevent HCl-induced chronic lung injury and pulmonary fibrosis in young (p24) C57BL/6J mice. Pre-pubertal (p24) C57BL/6J mice received a single intratracheal instillation of 0.1 N HCl and were treated with AT13387 (10 mg/kg, s.c., 3×/week for 30 days) beginning 24 h post-exposure. Bronchoalveolar lavage fluid (BALF) analysis, lung function measurements, histological assessment (Ashcroft fibrosis score), and Western blot analysis of key signaling mediators were performed. Additionally, publicly available single-nucleus RNA sequencing (snRNA-Seq) data from a cohort of 13 infants with bronchopulmonary dysplasia (BPD) and 11 age-matched controls were analyzed to evaluate HSP90 isoform expression in human pediatric lung disease. AT13387 significantly reduced BALF white blood cell concentration without affecting total BALF protein levels. Importantly, AT13387 did not impair normal weight gain or development over the 30-day observation period. AT13387 abrogated HCl-induced expression of TGF-β1, phosphorylation of HSP90, ERK1/2, SMAD2, IκBα, and upregulation of the inflammasome NLRP3. Additionally, AT13387 prevented changes in lung function dynamics and reduced the Ashcroft fibrosis score. Analysis of the human snRNA-Seq BPD dataset revealed a widespread pan-overexpression of all three HSP90 isoforms, i.e., HSP90AA1, HSP90AB1, and HSP90B1. These findings suggest that the HSP90 inhibitor AT13387 exhibits strong antidotal properties against HCl-induced chronic lung injury and pulmonary fibrosis in a pre-clinical pediatric model and identify HSP90 as a conserved therapeutic target in pediatric chronic lung disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HSP90 Heat-Shock ProteinsLung InjuryBronchopulmonary DysplasiaAnimalsMiceMice, Inbred C57BLMaleHydrochloric AcidHumansDisease Models, AnimalLungBronchoalveolar Lavage Fluid

Stichwörter der Autor:innen

AT13387HSP90NLRP3TGF-βbronchopulmonary dysplasiachildrenchronic lung injuryhydrochloric acidonalespibpre-pubertalpulmonary fibrosissnRNA-Seq

Substanzen

HSP90 Heat-Shock ProteinsHydrochloric Acid

Autor:innen und Institutionen

  • Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk, VA 23509, USA.
  • School of Medical Diagnostic & Translational Sciences, Ellmer College of Health Sciences, Old Dominion University, Norfolk, VA 23509, USA.
  • Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Eastern Virginia Medical School, Macon and Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, VA 23508, USA.

ORCID-Profile: Pavel A Solopov, John D Catravas, Ruben M L Colunga Biancatelli

Förderung

  • NIEHS NIH HHS
  • Old Dominion Research Foundation
  • Pam and Rich Nuccitelli Foundation
  • CounterACT Program

Zitieren

APA

Solopov, P. A., Dimitropoulou, C., Catravas, J. D., & Colunga Biancatelli, R. M. L. (2026). HSP90 Inhibitor, AT13387 Mitigates Chronic Lung Injury in Pre-Pubertal Mice: A Therapeutic Axis in Bronchopulmonary Dysplasia. Biomolecules. https://doi.org/10.3390/biom16091320

Vancouver

Solopov PA, Dimitropoulou C, Catravas JD, Colunga Biancatelli RML. HSP90 Inhibitor, AT13387 Mitigates Chronic Lung Injury in Pre-Pubertal Mice: A Therapeutic Axis in Bronchopulmonary Dysplasia. Biomolecules. 2026. doi:10.3390/biom16091320

BibTeX
@article{Solopov2026,
  author = {Solopov, Pavel A and Dimitropoulou, Christiana and Catravas, John D and Colunga Biancatelli, Ruben M L},
  title = {HSP90 Inhibitor, AT13387 Mitigates Chronic Lung Injury in Pre-Pubertal Mice: A Therapeutic Axis in Bronchopulmonary Dysplasia},
  journal = {Biomolecules},
  year = {2026},
  doi = {10.3390/biom16091320}
}
Kostenlos starten →